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Drug use in the intensive care unit
To the Editor: Drug use in the intensive care unit poses the
increased risk of nephrotoxicity. In this clinical setting two
typical errors should be avoided, namely overdosage and
underdosage—mainly of the anti-infective drugs. In his
valuable review on this topic, Mark A. Perazella suggested
adjusting the dose to the patient’s kidney function by using
the measured creatinine clearance (CrCl):1 ‘Maintenance
dose¼ standard dose (patient’s CrCl/normal CrCl), or Main-
tenance dosing interval¼ standard dosing interval (normal
CrCl/patient’s CrCl)’. However, the adjusted dose is not equal
to that clearance ratio. This has been shown by Luzius Dettli
using his classical two-step approach:2 The pharmacokinetic
parameters depend on kidney function according to a linear
function, and the dose must be adjusted to the pharmaco-
kinetic parameters in direct proportion to that change. With
greater drug clearance, the intercept of this linear function is
lower and the slope is higher, or the elimination half-life in
patients with failing kidney function (T1/2fail) differs from the
half-life value in normal individuals (T1/2norm). Bringing both
steps into one equation yields the following solution:
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In addition, and as proposed in the Kidney Disease:
Improving Global Outcomes update, the creatinine clearance
could better be replaced by any of the common estimates of the
glomerular ﬁltration rate, such as the Cockcroft & Gault
equation, the Modiﬁcation of Diet in Renal Disease equation, or
the Chronic Kidney Disease Epidemiology Collaboration
formula.3 All three GFR estimates are based on simple serum
creatinine measurements.
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The Author Replies: Two letters to the editor raise
important issues about drug dosing and extracorporeal drug
clearance in intensive care unit patients.1,2 Critically ill
patients often suffer from acute kidney injury (AKI) and
multi-organ failure; they are the most complicated group for
whom nephrologists must provide care.3 By the nature of
their acute and chronic disease processes, they require
numerous pharmaceutical agents. Calculating the appropriate
dose is challenging and fraught with difﬁculty, as most
pharmacokinetic parameters are disrupted in critically ill
patients with AKI, especially when there is coexistent liver
injury. Changes in volume of distribution and altered drug
metabolism can lead to either lack of efﬁcacy or overt toxicity.
In addition, renal drug excretion is frequently abnormal,
difﬁcult to predict, quite dynamic, and further altered when
renal replacement therapy is added to the mix.
Dr Keller astutely points out the limitations of creatinine
clearance and its use as a ratio to determine drug dose
adjustments. I concede this point, but emphasize that my
intent was to bring the reader’s attention to the need for dose
adjustment in these patients because of their underlying
pharmacokinetic disturbances.3 All glomerular ﬁltration rate
(GFR) estimates in critically ill patients with AKI and/or
multi-organ failure perform poorly, thereby limiting their
utility in accurately dosing drugs. The Kidney Disease:
Improving Global Outcomes drug dosing recommendations,
which were published after my paper was written, are very
helpful.4 However, these formulas often signiﬁcantly over-
estimate GFR, and the GFR ranges utilized for drug dose
adjustment are anything but granular (o10, 10–50, 450).
Many of these problems would disappear if we could simply
measure drug concentrations. Until this is available for all
drugs, the goal of my drug-dosing guides was to familiarize
the reader with pharmacokinetic concepts and provide a
simple approach to dose adjustment (loading vs. maintenance
dose). Most importantly, I emphasize the need for a col-
laborative working relationship between clinical pharmacists
and critical-care nephrologists.
Barrantes and Horwedel appropriately note that attentive
care must be undertaken when dosing antibiotics in patients
on extended dialysis (ED). While pharmacokinetic drug
studies are limited for most continuous renal replacement
therapy modalities, ED is an even more understudied area,
although it has received recent interest.5 As the authors point
out, drug efﬁcacy and toxicity are related not only to the dose
administered, but also to the timing of the dose in relation
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